Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection

7Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective: To determine the value contribution of cabotegravir + rilpivirine, the first injectable every two months long-acting antiretroviral regimen, using multi-criteria decision analysis. Method: The study was developed in two phases. After a small pilot, a field work study with a larger number of multidisciplinary experts was carried out. Seven single-tablet regimens, currently recommended by the GeSIDA guidelines, were selected as comparators. EVIDEM methodology was followed, with a framework composed by 12 quantitative and 5 contextual criteria. Mean and standard deviations were calculated for quantitative criteria (1 to 5 scale; comparative criteria -5 to +5), whereas qualitative criteria were analyzed as percentages of experts that considered a positive, neutral or negative impact for the National Health System. Results: 35 experts participated in the study. Human immunodeficiency virus-1 infection was considered severe (mean ± standard deviation: 3.0 ± 1.0), with moderate size of affected population (2.7 ± 1.2) and unmet needs (2.8 ± 1.0). Minimal differences were found in comparative efficacy/effectiveness (0.1 ± 0.5), safety/tolerability (-0.5 ± 0.7), and cost criteria: cost of the intervention (0.5 ± 2.0), other medical costs (0.2 ± 1.8) and non-medical/indirect costs (0.5 ± 1.6). Experts perceived an improvement with cabotegravir + rilpivirine long-acting, compared to current daily oral single-tablet regimens, in patient-reported outcomes (2.7 ± 1.4). Therapeutic benefit of the long-acting regimen was considered moderate-to-high (3.5 ± 1.2). Experts considered the evidence provided by cabotegravir + rilpivirine long-actingrobust (4.3 ± 0.8), with elevated consensus on its future recommendation in guidelines (3.2 ± 1.0). In contextual criteria, most experts considered positive the impact on population priorities and access (91%), common goal and specific interests (63%) and political, historical, and cultural context criteria (60%). Impact was neutral in system capacity and appropriate use (40%), and opportunity costs and affordability criteria (51%). Result of the weighted global value contribution of cabotegravir + rilpivirine long-acting was 0.34 (-1 to +1 scale), with Patient Reported Outcomes comparative criterion bringing the highest added value. Conclusions: Cabotegravir + rilpivirine long-acting provides added value contribution to human immunodeficiency virus-1 management in Spain compared to daily oral single-tablet regimens. Patient Reported Outcomes and therapeutic benefit of cabotegravir + rilpivirine long-acting were highly valued by experts, as the expected benefit in adherence and stigma-related issues would improve overall quality of life for people living with human immunodeficiency virus-1.

Figures

References Powered by Scopus

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

813Citations
N/AReaders
Get full text

Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between hiv-infected and uninfected individuals: The age H IV cohort study

634Citations
N/AReaders
Get full text

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression

353Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain

4Citations
N/AReaders
Get full text

Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments

1Citations
N/AReaders
Get full text

Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Calleja-Hernández, M. Á., Martinez-Sesmero, J. M., Vallejo-Aparicio, L. A., Hernández-Novoa, B., Badia, X., Rivero, A., … Moreno y Sofía Huete, S. (2022). Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection. Farmacia Hospitalaria, 46(4), 208–214. https://doi.org/10.7399/fh.11845

Readers over time

‘22‘23‘240481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

67%

Researcher 2

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

40%

Pharmacology, Toxicology and Pharmaceut... 3

30%

Nursing and Health Professions 2

20%

Agricultural and Biological Sciences 1

10%

Save time finding and organizing research with Mendeley

Sign up for free
0